Is Cell-free fetal DNA testing a safe option for women in a high-risk population after combined first-trimester testing?
Fiche publication
Date publication
janvier 2022
Journal
Journal of gynecology obstetrics and human reproduction
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BONNET Céline
Tous les auteurs :
Dap M, Caffin L, Perdriolle-Galet E, Bonnet C, Morel O
Lien Pubmed
Résumé
Our study aimed to examine the relevance of cell-free fetal DNA (cfDNA) testing on the screening of chromosomal defects and the issue of pregnancies in patients with a risk over 1:50 after the first-trimester combined test.
Mots clés
cell-free fetal DNA, combined first trimester screening, high risk, non-invasive prenatal testing, trisomy 21
Référence
J Gynecol Obstet Hum Reprod. 2022 Jan 31;:102329